Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$6.02
-8.4%
$8.46
$1.95
▼
$12.43
$6.40B0.1719.79 million shs10.56 million shs
Insmed, Inc. stock logo
INSM
Insmed
$141.33
-2.2%
$110.85
$90.39
▼
$212.75
$31.00B0.833.06 million shs6.22 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.60
-0.9%
$37.22
$19.96
▼
$42.50
$27.97B1.236.57 million shs3.97 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$554.73
-0.8%
$548.85
$455.63
▼
$614.23
$23.63B0.49551,297 shs367,682 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-1.94%+8.24%-25.09%-15.66%+207.01%
Insmed, Inc. stock logo
INSM
Insmed
+20.58%+22.35%+51.00%+14.86%-29.03%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.59%-2.58%+11.57%+7.33%+91.54%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-3.16%-5.77%+0.94%+8.96%+17.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$6.02
-8.4%
$8.46
$1.95
▼
$12.43
$6.40B0.1719.79 million shs10.56 million shs
Insmed, Inc. stock logo
INSM
Insmed
$141.33
-2.2%
$110.85
$90.39
▼
$212.75
$31.00B0.833.06 million shs6.22 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.60
-0.9%
$37.22
$19.96
▼
$42.50
$27.97B1.236.57 million shs3.97 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$554.73
-0.8%
$548.85
$455.63
▼
$614.23
$23.63B0.49551,297 shs367,682 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-1.94%+8.24%-25.09%-15.66%+207.01%
Insmed, Inc. stock logo
INSM
Insmed
+20.58%+22.35%+51.00%+14.86%-29.03%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.59%-2.58%+11.57%+7.33%+91.54%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-3.16%-5.77%+0.94%+8.96%+17.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$16.00166.00% Upside
Insmed, Inc. stock logo
INSM
Insmed
2.92
Moderate Buy$196.5239.05% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.79
Moderate Buy$46.8221.30% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.69
Moderate Buy$676.4021.93% Upside

Current Analyst Ratings Breakdown

Latest IBRX, ROIV, INSM, and UTHR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Reiterated RatingSell (D-)
11/16/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$46.00 ➝ $48.00
11/10/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$47.00 ➝ $48.00
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
DowngradeBuy (B-) ➝ Hold (C+)
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Initiated CoverageBuy$660.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetOverweight$700.00 ➝ $703.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetBuy$675.00 ➝ $700.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetOutperform$697.00 ➝ $725.00
11/4/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Set Price Target$720.00
11/4/2026
Insmed, Inc. stock logo
INSM
Insmed
Initiated CoverageBuy$220.00
11/4/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetBuy$728.00 ➝ $768.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M56.48N/AN/A($1.08) per share-5.57
Insmed, Inc. stock logo
INSM
Insmed
$606.42M51.13N/AN/A$3.31 per share42.70
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,385.61N/AN/A$6.34 per share6.09
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.19B7.41$31.70 per share17.50$147.36 per share3.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$1.08N/AN/AN/A-607.79%N/A-54.83%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$2.82N/A227.95N/A-39.85%-96.38%-32.55%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.63N/AN/AN/A-838.21%-22.03%-20.55%2/5/2027 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$26.5020.9317.313.8438.61%19.18%17.07%N/A

Latest IBRX, ROIV, INSM, and UTHR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.01$5.71-$0.30$5.71$781.14 million$832.50 million
10/29/2026Q3 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.3827-$0.46-$0.0773-$0.46$500.36 million$524.43 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
4.27
4.27
Insmed, Inc. stock logo
INSM
Insmed
0.77
2.86
2.59
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
15.56
15.56
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
4.61
4.29

Institutional Ownership

CompanyInstitutional Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
66.10%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
8.80%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
6911.06 billion360.64 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664219.38 million214.77 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
721724.56 million660.80 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.59 million38.93 millionOptionable

Recent News About These Companies

United Therapeutics Reports First Pig Kidney Transplant in Trial
United Therapeutics (NASDAQ:UTHR) CEO Sells $5,583,530.00 in Stock
United Therapeutics (UTHR) Gets a Hold from Morgan Stanley
FY2026 Earnings Forecast for UTHR Issued By HC Wainwright
Analysts Issue Forecasts for UTHR FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$6.02 -0.56 (-8.45%)
Closing price 03:58 PM Eastern
Extended Trading
$6.10 +0.09 (+1.48%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Insmed stock logo

Insmed NASDAQ:INSM

$141.33 -3.13 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$142.28 +0.95 (+0.67%)
As of 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$38.60 -0.36 (-0.93%)
Closing price 03:58 PM Eastern
Extended Trading
$38.65 +0.05 (+0.14%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$554.73 -4.37 (-0.78%)
Closing price 04:00 PM Eastern
Extended Trading
$550.30 -4.43 (-0.80%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.